# IZABRIGHT-Breast01

Source: https://onco.cc/trials/izabright-breast01/  
OnCo record `izabright-breast01` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IZABRIGHT-Breast01 is the global first-line trial of the EGFR×HER3 bispecific ADC in triple-negative breast cancer.

## Summary

IZABRIGHT-Breast01, trial NCT06926868 sponsored by Bristol Myers Squibb, is the global first-line trial of the EGFR by HER3 bispecific antibody-drug conjugate izalontamab brengitecan in metastatic triple-negative breast cancer patients ineligible for PD-1 or PD-L1 inhibitors, comparing it with chemotherapy. It plans to enrol 570 patients, directly competes for the populations studied in ASCENT-03 and TROPION-Breast02, and is ongoing with no results. OnCo links it to triple-negative breast cancer, izalontamab brengitecan and the TNBC roadmap. Whether a bispecific ADC that succeeded in a Chinese phase 3 can match or beat the approved TROP2 ADCs in a global first-line population is the question it exists to answer.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-04
- Registry id: NCT06926868
- Phase: 2/3
- Setting: First-line metastatic TNBC ineligible for PD-(L)1 inhibitors: iza-bren vs chemotherapy
- Sponsor: BMS
- Enrolled: 570
- Replication: Ongoing; no results.

## Sources

- ClinicalTrials.gov NCT06926868: https://clinicaltrials.gov/study/NCT06926868

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/)
- roadmaps: [TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line](https://onco.cc/roadmaps/tnbc-history/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- ideas: [Trials that include, and report, brain metastases in triple-negative breast cancer](https://onco.cc/ideas/idea-tnbc-brain-metastasis-trials/)

---
JSON: https://onco.cc/api/v1/entities/izabright-breast01.json